Treatment of aggressive bone angiomas using gelled alcohol sclerotherapy
Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy
This study is testing a new non-surgical treatment for aggressive bone angiomas to see if combining two procedures can help patients feel better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 11 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 1 site (Saint-Priest-en-Jarez) |
| Trial ID | NCT06607731 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility, safety, and efficacy of a non-surgical treatment protocol for aggressive bone angiomas, specifically vertebral hemangiomas. The approach combines transarterial embolization with percutaneous radiopaque gelled ethanol sclerotherapy in a single procedure, followed by vertebroplasty in a subsequent procedure. Data will be collected from medical records of patients treated at the University Hospital of Saint-Etienne. The study aims to provide insights into the effectiveness of this innovative treatment method.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with aggressive bone angiomas who have undergone gelled alcohol sclerotherapy.
Not a fit: Patients who have not been treated with gelled alcohol sclerotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a less invasive option for patients suffering from aggressive bone angiomas.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne. Exclusion Criteria: * Patients no treated by gelled alcohol sclerotherapy.
Where this trial is running
Saint-Priest-en-Jarez
- CHU de Saint-Etienne — Saint-Priest-en-Jarez, France (Recruiting)
Study contacts
- Principal investigator: Sylvain GRANGE, MD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Sylvain GRANGE, MD
- Email: sylvain.grange@chu-st-étienne.fr
- Phone: (0)477829066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.